Last reviewed · How we verify
HDC
HDC is a homeopathic combination remedy designed to support detoxification and drainage of metabolic waste products.
HDC is a homeopathic combination remedy designed to support detoxification and drainage of metabolic waste products. Used for Detoxification support (homeopathic indication).
At a glance
| Generic name | HDC |
|---|---|
| Also known as | Lymphdiaral Basistropfen |
| Sponsor | Pascoe Pharmazeutische Praeparate GmbH |
| Modality | Small molecule |
| Therapeutic area | Homeopathic/Complementary Medicine |
| Phase | Phase 3 |
Mechanism of action
HDC appears to be a classical homeopathic preparation from Pascoe, a German manufacturer specializing in phytopharmaceuticals and homeopathic remedies. The product likely combines multiple homeopathic ingredients intended to stimulate the body's natural elimination pathways. Homeopathic mechanisms are not established through conventional pharmacology but rather through traditional homeopathic theory of potentization and constitutional support.
Approved indications
- Detoxification support (homeopathic indication)
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Corticosteroid Tapering in Sarcoidosis (NA)
- Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome (PHASE2)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDC CI brief — competitive landscape report
- HDC updates RSS · CI watch RSS
- Pascoe Pharmazeutische Praeparate GmbH portfolio CI